AUSTIN, Texas & TORONTO--(BUSINESS WIRE)--Triumvira Immunologics, a privately-held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today announced the appointment of Cynthia (Cindy) Collins to the Board of Directors.
“We are very pleased that Cindy has joined Triumvira,” said President and CEO of Triumvira Immunologics, Paul Lammers. “Cindy brings extensive experience in leading and managing gene and cell therapy companies as well as strategic positioning, oncology drug development and product commercialization. We look forward to her contributions as we build our company and work to bring new treatments to patients in need.”
In her most recent role, Ms. Collins was the CEO of Human Longevity, Inc., the genomics-based, health intelligence company creating the world’s largest and most comprehensive database of whole genome, phenotype and clinical data.
Prior to her time at Human Longevity, Inc., Ms. Collins was CEO/GM of General Electric’s Healthcare Cell Therapy Business, Lab Businesses and Clarient Diagnostics. She was also the President and CEO of GenVec, Inc., and spent 17 years with Baxter Healthcare in a variety of executive roles, including President of Oncology, Vice President of Strategy and Portfolio Management of BioScience, Vice President & General Manager of Cell Therapies, and Vice President of Business Development of Transfusion Therapies. Ms. Collins is a member of the Board of Directors for the Analytical Life Science and Diagnostics Association (ALDA), Alliance for Regenerative Medicine (ARM) Foundation, and Cavidi AB as well as a strategic advisor to Phase Holographic Imaging. Ms. Collins received her BS degree in Microbiology from the University of Illinois, Urbana, and her MBA from The University of Chicago Booth School of Business.
“I am excited to be a member of the Board of Directors and to be working alongside such an experienced management team at Triumvira,” said Ms. Collins. “Triumvira’s proprietary T Cell-Antigen Coupler (TAC) offers diverse opportunities in cancers and hematological malignancies. I look forward to helping advance the company’s goals.”
About Triumvira Immunologics
Triumvira Immunologics is an immuno-oncology company, developing a novel platform for engineering T cells to attack both liquid and solid tumors. Triumvira’s proprietary T Cell-Antigen Coupler (TAC) co-opts the natural T Cell receptor biology and functions. This approach operates through the native T cell receptor, in turn optimizing selectivity and signaling, and has demonstrated superiority over CAR-T in pre-clinical studies. Led by a management team with decades of drug development expertise, Triumvira’s pipeline includes multiple oncology trials slated to enter the clinic in 2019.